Redhill Biopharma Ltd
RDHL
Company Profile
Business description
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is dedicated to advancing its development pipeline of clinical-stage therapeutic candidates. It also commercializes GI-related products in the U.S., including Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). Currently, the company's pipeline consists of five therapeutic candidates: Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, the majority of which are in clinical development.
Contact
21 Ha’arba’a Street
Tel Aviv6473921
ISRT: +972 35413131
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - Specialty & Generic
Fiscal Year End
31 December 2026
Employees
35
Stocks News & Analysis
stocks
Magellan merger modestly dilutive
Our view on how shareholders should respond to the Magellan merger.
stocks
ASX listed gold miner under pressure due to lower production
Shares have dropped nearly 20% since lowering 2026 volume guidance.
stocks
3 ASX opportunities after earnings season
Uncovering key opportunities following February’s results.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,847.70 | 14.20 | 0.16% |
| CAC 40 | 7,973.25 | 1.24 | -0.02% |
| DAX 40 | 23,577.92 | 153.00 | -0.64% |
| Dow JONES (US) | 46,678.07 | 315.19 | -0.67% |
| FTSE 100 | 10,325.91 | 77.69 | -0.75% |
| HKSE | 26,025.42 | 156.88 | 0.61% |
| NASDAQ | 22,405.82 | 73.70 | -0.33% |
| Nikkei 225 | 55,239.40 | 1,539.01 | 2.87% |
| NZX 50 Index | 13,315.60 | 133.37 | 1.01% |
| S&P 500 | 6,688.56 | 27.53 | -0.41% |
| S&P/ASX 200 | 8,640.60 | 14.40 | 0.17% |
| SSE Composite Index | 4,062.98 | 13.08 | 0.32% |